Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 plus nab-paclitaxel versus S-1 plus gemcitabine as first-line therapy for unresectable pancreatic cancer
ChiCTR1900024588Phase 3Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pancreatic cancer (PC) comparing S-1 + nab-paclitaxel with S-1 + gemcitabine (2 arms). Primary endpoint: Progression-free survival. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
tegafurpaclitaxelgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR1900024588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024588.